PARIJS & WALTHAM, Mass. – (BUSINESS WIRE) – Echosens, een hoogtechnologisch bedrijf dat de FibroScan^® productfamilie aanbiedt, is verheugd aan te kondigen dat het is gekozen voor de serie “Global Thought Leaders” die wordt uitgezonden op CBS News. Bekijk een korte video waarin het baanbrekende werk van het bedrijf wordt belicht bij de ontwikkeling van essentiële medische hulpmiddelen, waaronder FibroScan^® een niet-invasieve oplossing voor het meten van de leverelasticiteit en het vetgehalte van de lever op het zorgpunt.

“We zijn verheugd dat we zijn geselecteerd door CBS News en trots op de video die is gemaakt op ons internationale hoofdkantoor in Parijs, waarin de essentie van Echosens wordt vastgelegd, inclusief interviews met enkele van onze topleiders en een clinicus die een FibroScan^® onderzoek uitvoert met haar patiënt, ”Zegt Dominique Legros, Group CEO, Echosens. “Betrouwbaar, nauwkeurig en betaalbaar, FibroScan^® is ontworpen om een ​​groeiende epidemie van leverziekte aan te pakken. Nonalcoholic fatty liver disease (NAFLD) treft ongeveer 25% van de wereldwijde bevolking en maar liefst 6% wordt getroffen door NASH, dat naar verwachting met 63% zal toenemen tegen 2030.”

CBS News “Global Thought Leaders” Series Features Echosens: Video Showcases FibroScan® as Medical Gold Standard

PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, a high-technology company offering the FibroScan^® family of products, is pleased to announce that it has been chosen for the “Global Thought Leaders” series broadcast on CBS News. View a short video highlighting the Company’s groundbreaking work in the development of vital medical resources, including FibroScan^®, a noninvasive solution for measuring liver elasticity and fat content of the liver at the point of care.

“We’re pleased to be selected by CBS News and proud of the video created at our international headquarters in Paris which captures the essence of Echosens, including interviews with some of our top leaders and a clinician performing a FibroScan^® exam with her patient,” says Dominique Legros, Group CEO, Echosens. “Reliable, accurate and affordable, FibroScan^® is designed to address a growing liver disease epidemic. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the worldwide population and as many as 6% are affected by NASH, which is expected to increase by 63% by 2030.”

FibroScan^® has been supported by over 2,500 peer reviewed publications and 70 international guidelines. FibroScan^® can be performed by a trained operator (physician, nurse, medical assistant), and is covered by Medicare, Medicaid and most insurance plans.

Echosens’ also offers Fast^™—available on the myFibroScan app— a FibroScan^®-based score for the identification of at-risk NASH in NAFLD patients. Fast^™ is a combination of three components: two physical biomarkers: liver stiffness (LSM by VCTE™) and CAP™, plus AST, a readily available blood marker of inflammation.

Legros states, “We are proud to be part of leading healthcare organizations working at the forefront of transforming quality of life, diagnosis and treatment to excel and fuel the future.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan^®, the non-invasive solution for comprehensive management of liver health. FibroScan^® is recognized worldwide and validated by over 2,500 peer reviewed publications and 70 international guidelines. Echosens has made FibroScan^® available in over 100+ countries enabling millions of liver examinations worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005039/en/

Contacts

Media:
Brittany Tedesco

CPR Communications

btedesco@cpronline.com
201.641.1911 x 14